AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02711033 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted total gastrectomy
Description: When patients with advanced proximal gastric cancer are randomized in the laparoscopic-assisted total gastrectomy (LATG) group, they will received LATG with spleen-preserving splenic hilum lymph nodes dissection.
Study NCT02711033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open total gastrectomy
Description: When patients with advanced proximal gastric cancer are randomized in the open total gastrectomy (OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
Study NCT00945334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: 500 mg po bid for 14 days
Study NCT02041793 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cystogastrostomy
Description: Patients undergo drainage of pseudocyst by laparoscopic technique
Study NCT02041793 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic cystogastrostomy
Description: Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance
Study NCT02370849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: cisplatin: 30 mg/m2 iv. infusion on day 1, 2 every 3 weeks
Study NCT02370849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin: 30 mg/m2 iv. infusion on day 1, 2 every 3 weeks
Study NCT02370849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1: 40 mg/m2 bid , 2 weeks on, 1 week off ；
Study NCT02370849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1: 40 mg/m2 bid , 2 weeks on, 1 week off ；
Study NCT01009801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin-eluting beads
Description: Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
Study NCT01009801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin-eluting beads
Description: Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
Study NCT01009801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
Study NCT01009801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
Study NCT03184298 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surveys
Description: The purpose of the surveys is to collect quantitative data to determine the relative impact of the intervention program on participants' sexual behaviors and alcohol use.
Study NCT03184298 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interviews
Description: These Motivational Interviews aim to promote change in behavior through open-ended questions, affirmations, and reflections.
Study NCT03184298 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group Discussions
Description: The purpose of the group workshop is to create discussions surrounding perceived and collective social norms found among male soldiers that have been connected to sexual aggression. These discussions are used to promote bystander intervention among participants and help identify the prosocial attitudes that may be more common than previously perceived.
Study NCT03176940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
Study NCT00006708 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: 5 μg/kg/day subcutaneous injection on Days 5-12 every 21 days for 3 cycles.
Study NCT00006708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 μg/kg/day subcutaneous injection on Days 5-12 every 21 days for 3 cycles.
Study NCT00006708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00006708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Study NCT00006708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00006708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Study NCT00006708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00006708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide
Study NCT00006708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT03611933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: position change applied at different times
Description: Time 1 - in the first fifth minute after the procedure supine position in which the HOB was elevated 15° Time 2 - in the first hour low fowler's position were given in which the HOB was elevated 15-30° Time 3 - in the third hour semi high fowler's position were given in which the HOB was elevated 30-45° Time 4 - in the fourth hour left or right lateral position were given in which the HOB was elevated 15° Time 5 - in the fifth hour low fowler's position were given in which the HOB was elevated 15-30° Time 6 - in the sixth hour standard fowler's position were given in which the HOB was elevated 45-60°
Study NCT01165021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
Study NCT01165021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
Study NCT01165021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Administered orally.
Study NCT01165021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Administered Intramuscular injection.
Study NCT01165021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally.
Study NCT04086563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation
Description: look at a clip of a hand doing neurodynamic exercises.
Study NCT04086563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action observation
Description: look at a clip of a hand doing neurodynamic exercises.
Study NCT04086563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: With a mirror glasses on, do the neurodynamic exercises with the non-dominant hand while the patient is looking at the dominant hand
Study NCT04086563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: With a mirror glasses on, do the neurodynamic exercises with the non-dominant hand while the patient is looking at the dominant hand
Study NCT04086563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic exercises
Description: active movement of the dominant hand. Do neurodynamic exercises.
Study NCT04086563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodynamic exercises
Description: active movement of the dominant hand. Do neurodynamic exercises.
Study NCT04086563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength
Description: Execute a short strength training for the dominant hand
Study NCT02049255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroprocaine
Description: The Group Chloroprocaine will receive: Chloroprocaine: 50 mg in rachianesthesia
Study NCT02049255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marcaine
Description: The Group Marcaine will receive: Marcaine: 12,5 mg in rachianesthesia
Study NCT01810198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac CT
Description: Perform a non-invasive Cardiac CT Angiogram
Study NCT01810198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive Coronary Angiography
Description: Patient undergoes Invasive Coronary Angiography
Study NCT00579124 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CliniMACs
Description: T and B Cell depletion
Study NCT00945334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo for 14 days tid
Study NCT00945334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550 mg po tid
Study NCT02129309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm plethysmography
Description: Dose response study
Study NCT02129309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haemodynamic studies
Description: Dose response study
Study NCT00808509 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 40 mg every other week via subcutaneous injection
Study NCT00808509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: At least 10 mg/week administered orally or subcutaneously
Study NCT00808509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: At least 10 mg/week administered orally or subcutaneously
Study NCT04666688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYT-200
Description: monoclonal antibody (mAb), targeting galectin-9 protein
Study NCT04666688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: anti-PD-1 monoclonal antibody
Study NCT04666688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/nab-paclitaxel
Description: chemotherapy
Study NCT04397289 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Heparin and Rivaroxaban
Description: Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation
Study NCT04397289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin and Rivaroxaban
Description: Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation
Study NCT04347525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CaCBT based guided self help using Khushi aur Khatoon Manual
Description: CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
Study NCT03355352 — intervention group
Intervention type: DRUG
Intervention: Sufentanil
Description: Sufentail sublingual 15ug nanopills
Study NCT01992016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: 1000mg given orally twice daily for 1 day (2 doses).
Study NCT02857283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filtered Air
Description: Participants will be exposed to filtered clean air
Study NCT02857283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health and Exposure Tracker (HET)
Description: Ozone and heart rate tracker
Study NCT01765751 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Cervical Distraction
Description: Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.
Study NCT01765751 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Manual Cervical Distraction
Description: Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.
Study NCT01367561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Study NCT01367561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Methylnaltrexone (MNTX)
Study NCT01367561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02089243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation therapy
Description: The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes.
Study NCT02089243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resective surgery
Description: The experienced neurosurgery are responsible for the selection of surgical techniques employed for medically refractory medial temporal lobe epilepsy that provide an effective treatment with significant preservation of neurological function and acceptable surgical risks.
Study NCT03755440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody (SHR-1210)
Description: PD-1 antibody (SHR-1210), 200mg, ivdrip, every 2 weeks.
Study NCT03068468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: BIIB092 intravenous infusion on specified days
Study NCT03068468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion on specified days
Study NCT06749938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holistic Intervention
Description: * Aerobic Exercise Prescription. Each participant will be given instruction on an exercise program to progress to perform a total of 150 minutes/wk of moderate-vigorous aerobic activity (including any yoga practice they choose to do) with two days of strengthening exercises using exercise bands.~* Yoga Protocol and Meditation Exercise. Participants will be asked to practice three 75-min session days per week. The program will focus on developing breath and body awareness/control (pranayama), focused concentration, meditation, muscular strength, muscular endurance, and mobility (flexibility) training that involves the mind body spirit connection.~* Diet Intervention. Coaching for diet modification will be incorporated into the psychosocial support messaging.~* Psychosocial Support. Motivational strategies to enhance exercise compliance comprise of electronic messaging using the BlueJay Mobile-Health, (Livermore, CA). This tele-health HIPPA compliant allows private communication.
Study NCT04844957 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin D
Description: Clinical Study
Study NCT04844957 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Full automatic chemiluminescence measuring instrument
Description: Chemiluminescence immunoassay
Study NCT02915055 — intervention group
Intervention type: DRUG
Intervention: Ibuprofen 600 mg
Description: Ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN
Study NCT02915055 — intervention group
Intervention type: DRUG
Intervention: standard oxycodone/acetaminophen
Study NCT00773435 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea 100 mg/ml in liquid formulation
Description: 10 ml BID for 10 consecutive days at the start of 3 consecutive 30 day periods
Study NCT00773435 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 10 ml PO BID for 10 consecutive days at the beginning of 3 consecutive 30 day periods
Study NCT03147456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: (Cubitan Protein, Nutricia, Netherlands).
Description: Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient.
Study NCT03147456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: (preOp, Nutricia, Netherlands).
Description: contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes
Study NCT02959957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temocillin
Description: Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial temocillin administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
Study NCT02959957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefotaxime
Description: Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial cefotaxime administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
Study NCT02108743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol.
Description: 2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
Study NCT02108743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo
Description: Placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
Study NCT04619914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt
Description: CLOMID (clomiphene citrate tablets USP) is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-\[p-(2-chloro-1,2-diphenylvinyl)phenoxy\] triethylamine citrate (1:1)
Study NCT04619914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole (Femara; Novartis pharma AG, Basle, Switzerland)
Description: Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Study NCT01958541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention I
Description: Insomnia-focused behavioral treatment (4 sessions).
Study NCT01958541 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Intervention II
Description: Insomnia-focused behavioral treatment (4 sessions).
Study NCT00394069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0476, montelukast sodium
Description: Duration of Treatment: 14 Days
Study NCT03935308 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR guided Linear Accelerator
Description: The aim is to perform treatment planning to compute the highest feasible simultaneous boosting dose to the intraprostatic lesion while respecting normal tissue dose constraints. Patients will be treated with MR-guided localization and adaptive planning techniques.
Study NCT00552149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemox, Cetuximab
Description: GEMOX (Arms 1 and 2), every two weeks:~Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h~Cetuximab (ErbituxÒ) (Arm B only) every two weeks:~(chemotherapy will be started one hour after the end of the cetuximab infusion).~Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes
Study NCT00552149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemox, Cetuximab
Description: GEMOX (Arms 1 and 2), every two weeks:~Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h~Cetuximab (ErbituxÒ) (Arm B only) every two weeks:~(chemotherapy will be started one hour after the end of the cetuximab infusion).~Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes
Study NCT00577148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration
Study NCT00577148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rimonabant)
Description: Tablet, oral administration
Study NCT04083352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pruvit Ketomax Ketone Salt
Description: 6-week supplementation with ketone salts
Study NCT04083352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was taken for 6-weeks and was calorie and flavor matched to the ketone salt supplement.